{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:19:26Z","timestamp":1770891566159,"version":"3.50.1"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jneuroim.2019.577140","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T20:18:57Z","timestamp":1576613937000},"page":"577140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Tumor necrosis factor alpha -863C\/A polymorphism and Guillain-Barr\u00e9 Syndrome"],"prefix":"10.1016","volume":"339","author":[{"given":"Beuy","family":"Joob","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viroj","family":"Wiwanitkit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2019.577140_bb0005","doi-asserted-by":"crossref","first-page":"577064","DOI":"10.1016\/j.jneuroim.2019.577064","article-title":"Is there a significant association between tumor necrosis factor alpha -863C\/A polymorphism and the development of Guillain-Barr\u00e9 Syndrome?","volume":"337","author":"Carlos","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2019.577140_bb0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jneuroim.2017.06.005","article-title":"Tumor necrosis factor-alpha -863C\/A polymorphism is associated with Guillain-Barr\u00e9 syndrome in Bangladesh","volume":"310","author":"Jahan","year":"2017","journal-title":"J. Neuroimmunol."},{"issue":"10","key":"10.1016\/j.jneuroim.2019.577140_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.960","article-title":"Guillain-Barre syndrome outbreak in Peru: Association with polymorphisms in IL-17, ICAM1, and CD1","volume":"7","author":"Jaramillo-Valverde","year":"2019","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.jneuroim.2019.577140_bb0020","first-page":"31","article-title":"PRDM1 rs1010273 polymorphism and survival of patients with hepatitis B virus-related hepatocellular carcinoma","volume":"9","author":"Joob","year":"2019","journal-title":"Adv Lab Med Int."},{"key":"10.1016\/j.jneuroim.2019.577140_bb0025","first-page":"28","article-title":"Letter to editor: G12V and G12C mutations in the gene KRAS and association with prognosis in primary colorectal cancer","volume":"9","author":"Joob","year":"2019","journal-title":"Adv Lab Med Int."},{"issue":"6","key":"10.1016\/j.jneuroim.2019.577140_bb0030","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.medcli.2017.06.076","article-title":"TNF-\u03b1-308 polymorphism and therapeutic response of ankylosing spondylitis","volume":"150","author":"Joob","year":"2018","journal-title":"Med. Clin. (Barc.)"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572819305569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572819305569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:35:51Z","timestamp":1759048551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572819305569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":6,"alternative-id":["S0165572819305569"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577140","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor necrosis factor alpha -863C\/A polymorphism and Guillain-Barr\u00e9 Syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577140"}}